An Open Label, Phase 2 Trial Comparing Sorafenib And TACE in Advanced Hepatocellular Carcinoma With Portal Vein Invasion
Latest Information Update: 24 Jun 2022
At a glance
- Drugs Cisplatin (Primary) ; Doxorubicin (Primary) ; Iodised oil (Primary) ; Mitomycin (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms STAP
- 28 Apr 2016 Status changed from recruiting to discontinued.
- 03 Dec 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 16 Apr 2013 Planned End Date changed from 1 Sep 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.